The obesity epidemic: what is pharma doing?

obesity_big-1

Recent figures confirm a continuous rise in rates of overweight and obesity. Since the 1980s, the prevalence of both conditions has more than doubled worldwide. In 2014, more than half of the adult population was tackling weight issues, with 13% living with obesity and 39% being overweight. Even more alarming are the data concerning children; in 2014, 40 million children under the age of 5 years were either overweight or obese. The big question is: What is the pharmaceutical industry doing to help tackle this epidemic?

A new understanding of obesity

While excessive intake of high-energy foods in conjunction with reduced physical activity is the classic cause of obesity, associations with exposure to some endocrine disruptors (chemicals that interfere with hormonal balances) have also been put forward as potential causes. New insights such as this have provided pharma with some promising ways forward in the development of drugs to help people contending with weight issues and any associated impact to health and well-being.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical